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Background: The number of potential regimens of drug treat-
ment for TB is vast, meaning that evaluating each new treatment
against a control in separate two-arm trials requires a huge amount
of resources. There is, therefore, a need for innovative trial designs
that can evaluate drug regimens simultaneously.
Methods & Materials: TRUNCATE-TB (two-month regimens
using novel combinations to augment treatment effectiveness for
drug-sensitive tuberculosis) is a randomised, open-label, multi-
arm, multi-stage (MAMS), parallel group strategy trial. The MAMS
design has been applied successfuly in a trial of multiple regi-
mens for prostate cancer, and more recently in a TB trial. In the
MAMS design, the trial starts with multiple arms, and, as it pro-
gresses, recruitment to those arms that do not show sufﬁcient
promise on an early interim outcome measure are discontinued,
whilst recruitment to the control arm and remaining promising
novel boosted arms continues until sufﬁcient numbers of patients
have been enrolled to assess the outcome on the deﬁned primary
outcome. Recommendations about stoppingor continuing armsare
made by an Independent Data Monitoring Committee on the basis
of safety and efﬁcacy data.
Results: Up to 1080 adult patients with pulmonary TB (diag-
nosed using sputum GeneXpert) will be randomised at equal
probability to receive 6-months standard treatment as a control, or
to one of a number of boosted regimens (these regimens are combi-
nations of standard drugswith new or repurposed drugs including:
high-dose rifampicin, linezolid, clofazimine, bedaquiline, dela-
manid, rifapentine or levoﬂoxacin.
Conclusion: The primary aim of the trial is to determine
whether a strategy of treating drug-sensitive TB for 2 months
with one of a number of novel combination regimens and re-
treating relapse with a 6-month course of standard treatment
will be non-inferior to the standard WHO-recommended 6-month
treatment/8-month re-treatment approach in terms of TB sputum
culture status at 2 years after randomisation. The secondary aims
are to assess the possible advantages of the TRUNCATE-TB man-
agement strategy compared to the standard management strategy
from the patient perspective (including acceptability, quality of
life and clinical adverse events) and the programme perspective
(including treatment adherence, default, new drug resistance and
community transmission) as well as cost-effectiveness.
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